第三代抗癲癇發作藥物治療癲癇的應用指南_Journal of Epilepsy

Authors：

WU Xintong , CHEN Yangmei , FENG Li , 吳欣桐　譯 ,  周東　審

Corresponding?author：

周東　審, Email: zhoudong666@yahoo.de.cn

Keywords：

癲癇; 第三代抗癲癇發作藥物; 指南

DOI：

10.7507/2096-0247.202603011

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

目的基于對第三代抗癲癇發作藥物（anti-seizure medications，ASMs）治療癲癇的臨床研究的證據評價，從臨床實踐角度對第三代ASMs進行治療推薦，以提升對藥物的深入認識和提高臨床治療規范化水平。方法對第三代ASMs進行系統文獻檢索，參考2011版英國牛津大學循證醫學中心證據分級（Oxford Centre for Evidence-based Medicine，OCEBM）對納入的文獻評級并形成推薦意見，結合證據分級和藥物安全性特征對推薦意見進行強度分級。結果指南共納入10種第三代ASMs，包括普瑞巴林、盧非酰胺、拉考沙胺、吡侖帕奈、艾司利卡西平、布立西坦、司替戊醇、大麻二酚、西諾氨酯、芬氟拉明，并對13個臨床問題形成推薦意見。結論本指南針對第三代ASMs進行詳細證據評價和治療推薦，有助于幫助臨床醫生更好地了解第三代ASMs，并為臨床實踐提供指導。

Citation： WU Xintong, CHEN Yangmei, FENG Li. 第三代抗癲癇發作藥物治療癲癇的應用指南. Journal of Epilepsy, 2026, 12(3): 222-238. doi: 10.7507/2096-0247.202603011 Copy

1.	中國抗癲癇協會. 臨床診療指南. 癲癇病分冊. 人民衛生出版社, 2023.
2.	Global, regional, and national burden of epilepsy, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet Public Health, 2025, 10(3): e203-e227.
3.	HOPE OA, Harris KM. Management of epilepsy during pregnancy and lactation . BMJ 2023, 382: e074630.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.	Guignet M, Campbell A, White HS. Cenobamate (XCOPRI): Can preclinical and clinical evidence provide insight into its mechanism of action? Epilepsia, 2020, 61(11): 2329-2339.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
39.
40.
41.
42.
43.
44.
45.
46.
47.
48.
49.
50.
51.
52.
53.
54.
55.
56.
57.
58.
59.
60.
61.
62.
63.
64.
65.
66.
67.
68.
69.
70.
71.
72.
73.
74.
75.
76.
77.
78.
79.
80.
81.	Ma H, Zhu H, Chen F, et al. Chiron C, Tonnelier S, Rey EEpilepsia Open, 2023, 8(4): 1474-1483.
82.
83.
84.
85.
86.
87.
88.	M B effectiveness of Cenobamate as monotherapy: a retrospective claims-based analysis. American epilepsy society, 2023, 12: e3428.
89.
90.
91.
92.
93.
94.
95.
96.
97.
98.
99.
100.
101.
102.
103.
104.
105.
106.
107.
108.
109.
110.
111.
112.
113.
114.
115.
116.
117.
118.
119.
120.
121.
122.
123.
124.
125.
126.
127.
128.
129.
130.
131.
132.
133.
134.
135.
136.
137.
138.
139.
140.
141.
142.
143.
144.
145.
146.
147.
148.
149.
150.
151.
152.
153.
154.
155.
156.
157.
158.
159.
160.
161.
162.
163.
164.
165.
166.
167.
168.
169.
170.
171.
172.
173.
174.
175.
176.
177.
178.
179.
180.
181.
182.
183.
184.
185.
186.
187.
188.
189.
190.
191.
192.
193.
194.
195.
196.
197.
198.
199.
200.
201.
202.
203.
204.
205.
206.
207.
208.
209.	Lobanov OV, Bertrand M. Successful treatment of pediatric patient with Dravet syndrome with cenobamate: Case report. SAGE Open Med Case Rep, 2025, 13: 2050313x251324079.
210.
211.
212.
213.
214.	LABEL. LYRICA?CR (pregabalin) . Upjohn. FDA. 2024.
215.	LABEL. RUFINAMIDE. Norvium Bioscience. FDA. 2016.
216.	LABEL. VIMPAT?(lacosamide) . UCB. FDA. 2020.
217.	LABEL. FYCOMPA? (perampanel) . Catalyst Pharmaceuticals. FDA. 2023.
218.	LABEL. APTIOM? (eslicarbazepine acetate) . Sumitomo Pharma America. FDA. 2019.
219.	LABEL. BRIVIACT? (brivaracetam) . UCB. FDA. 2023.
220.	LABEL. DIACOMIT (stiripentol) . Biocodex SAS. FDA. 2022.
221.	LABEL. EPIDIOLEX? (cannabidiol) . Jazz Pharmaceuticals. FDA . 2024.
222.	LABEL. COPRI? (cenobamate tablets) . SK Life Science. FDA. 2024.
223.	LABEL. FINTEPLA? (fenfluramine) . UCB. FDA. 2023.

1. 中國抗癲癇協會. 臨床診療指南. 癲癇病分冊. 人民衛生出版社, 2023.
2. Global, regional, and national burden of epilepsy, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet Public Health, 2025, 10(3): e203-e227.
3. HOPE OA, Harris KM. Management of epilepsy during pregnancy and lactation . BMJ 2023, 382: e074630.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13. Guignet M, Campbell A, White HS. Cenobamate (XCOPRI): Can preclinical and clinical evidence provide insight into its mechanism of action? Epilepsia, 2020, 61(11): 2329-2339.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
39.
40.
41.
42.
43.
44.
45.
46.
47.
48.
49.
50.
51.
52.
53.
54.
55.
56.
57.
58.
59.
60.
61.
62.
63.
64.
65.
66.
67.
68.
69.
70.
71.
72.
73.
74.
75.
76.
77.
78.
79.
80.
81. Ma H, Zhu H, Chen F, et al. Chiron C, Tonnelier S, Rey EEpilepsia Open, 2023, 8(4): 1474-1483.
82.
83.
84.
85.
86.
87.
88. M B effectiveness of Cenobamate as monotherapy: a retrospective claims-based analysis. American epilepsy society, 2023, 12: e3428.
89.
90.
91.
92.
93.
94.
95.
96.
97.
98.
99.
100.
101.
102.
103.
104.
105.
106.
107.
108.
109.
110.
111.
112.
113.
114.
115.
116.
117.
118.
119.
120.
121.
122.
123.
124.
125.
126.
127.
128.
129.
130.
131.
132.
133.
134.
135.
136.
137.
138.
139.
140.
141.
142.
143.
144.
145.
146.
147.
148.
149.
150.
151.
152.
153.
154.
155.
156.
157.
158.
159.
160.
161.
162.
163.
164.
165.
166.
167.
168.
169.
170.
171.
172.
173.
174.
175.
176.
177.
178.
179.
180.
181.
182.
183.
184.
185.
186.
187.
188.
189.
190.
191.
192.
193.
194.
195.
196.
197.
198.
199.
200.
201.
202.
203.
204.
205.
206.
207.
208.
209. Lobanov OV, Bertrand M. Successful treatment of pediatric patient with Dravet syndrome with cenobamate: Case report. SAGE Open Med Case Rep, 2025, 13: 2050313x251324079.
210.
211.
212.
213.
214. LABEL. LYRICA?CR (pregabalin) . Upjohn. FDA. 2024.
215. LABEL. RUFINAMIDE. Norvium Bioscience. FDA. 2016.
216. LABEL. VIMPAT?(lacosamide) . UCB. FDA. 2020.
217. LABEL. FYCOMPA? (perampanel) . Catalyst Pharmaceuticals. FDA. 2023.
218. LABEL. APTIOM? (eslicarbazepine acetate) . Sumitomo Pharma America. FDA. 2019.
219. LABEL. BRIVIACT? (brivaracetam) . UCB. FDA. 2023.
220. LABEL. DIACOMIT (stiripentol) . Biocodex SAS. FDA. 2022.
221. LABEL. EPIDIOLEX? (cannabidiol) . Jazz Pharmaceuticals. FDA . 2024.
222. LABEL. COPRI? (cenobamate tablets) . SK Life Science. FDA. 2024.
223. LABEL. FINTEPLA? (fenfluramine) . UCB. FDA. 2023.

Journal of Epilepsy

第三代抗癲癇發作藥物治療癲癇的應用指南

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content